About Fuzionaire Theranostics
Fuzionaire Theranostics is a Healthcare company based in The Woodlands (United States) founded in 2018. It develops theranostics platform for cancer diagnostics and therapies via innovative chemistry. It operates on a B2B model. Fuzionaire Theranostics offers products and services including HetSiFA Platform and GRPR Theranostic Pair. Its focus areas include Biotech, Oncology, Theranostics and Medical Devices and Diagnostics. Similar companies include SOFIE, Mariana Oncology and Lantheus; 2 of its 3 listed similar companies have raised funding.
Company details
Fuzionaire Theranostics focuses on creating radiopharmaceuticals for theranostics, combining PET diagnostics and radioligand therapies. Using the HetSiFA platform derived from breakthroughs at Caltech, they produce chemically identical diagnostic and therapeutic agents. This enables personalized cancer care by targeting specific receptors, such as in prostate cancer. Based in the USA, they collaborate with institutions to scale treatments and address oncology needs, improving accessibility for patients.
- Headquarters The Woodlands, United States
- SectorsHealthcare
- Website fuzionairetx.com
Products & Services of Fuzionaire Theranostics
Fuzionaire Theranostics offers a comprehensive portfolio of products and services, including HetSiFA Platform and GRPR Theranostic Pair.
Enables creation of personalized cancer diagnostics and therapies.
Targets prostate cancer receptors for diagnostic and treatment purposes.
Similar companies to Fuzionaire Theranostics
Fuzionaire Theranostics has 3 listed similar companies in our database, 2 of them funded. They include SOFIE, Mariana Oncology and Lantheus.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sofie.com | 2008 | Culver, United States | $43.1M | 546 | Developer of molecular imaging systems and radio-pharmaceuticals | |
| marianaoncology.com | 2020 | Watertown, United States | $250M | 41 | Targeted radiopharmaceuticals for solid tumors are developed and pioneered. | |
| lantheus.com | 2008 | Billerica, United States | 834 | Developer of diagnostic imaging agents and targeted therapeutics |
Detailed similar companies of Fuzionaire Theranostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Fuzionaire Theranostics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Fuzionaire Theranostics
Fuzionaire Theranostics was founded in 2018.
Fuzionaire Theranostics is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.
Fuzionaire Theranostics focuses on creating radiopharmaceuticals for theranostics, combining PET diagnostics and radioligand therapies. Using the HetSiFA platform derived from breakthroughs at Caltech, they produce chemically identical diagnostic and therapeutic agents. This enables personalized cancer care by targeting specific receptors, such as in prostate cancer. Based in the USA, they collaborate with institutions to scale treatments and address oncology needs, improving accessibility for patients.
Fuzionaire Theranostics's top competitors include SOFIE, Mariana Oncology and Lantheus.
Fuzionaire Theranostics offers HetSiFA Platform and GRPR Theranostic Pair.